Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.

Autor: Mondaza-Hernandez JL; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain., Hindi N; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain., Fernandez-Serra A; Molecular Biology Department, Fundación Instituto Valenciano de Oncologia, Valencia, Spain., Ramos R; Pathology Department, University Hospital Son Espases, Mallorca, Spain., Gonzalez-Cámpora R; Pathology Department, Hospital Quironsalud, Cordoba, Cordoba, Spain., Gómez-Mateo MC; Department of Pathology, Hospital Universitario Miguel Servet, Zaragoza, Spain., Martinez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain., Lavernia J; Medical Oncology Department, Fundación Instituto Valenciano de Oncologia, Valencia, Spain., Lopez-Pousa A; Medical Oncology Department, Sant Pau Hospital, Barcelona, Spain., Laínez N; Department of Medical Oncology, Complejo Hospitalario de Navarra Pamplona, Spain., Martinez-Garcia J; Medical Oncology Department, University Hospital Virgen de la Arrixaca, Murcia, Spain., Valverde C; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Vaz-Salgado MÁ; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, CIBERONC, Madrid, Spain., Garcia-Plaza G; Department of Surgery, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain., Marin-Borrero I; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain., Carrillo-Garcia J; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain., Martin-Ruiz M; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain., Romero P; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain., Gutierrez A; Hematology Department, Hospital Son Espases/IdISBa, Palma de Mallorca, Spain., López-Guerrero JA; Molecular Biology Department, Fundación Instituto Valenciano de Oncologia, Valencia, Spain., Moura DS; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain., Martin-Broto J; Health Research Institute Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Reyes Católicos 2, Madrid 28040, Spain.; University Hospital General de Villalba, Madrid, Spain.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Nov 04; Vol. 16, pp. 17588359241293951. Date of Electronic Publication: 2024 Nov 04 (Print Publication: 2024).

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).

Autor: Sepúlveda-Sánchez JM; Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain. sepulvedasanchez@seom.org., Gil-Gil M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Alonso-García M; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Vaz Salgado MÁ; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Vicente E; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Mesía Barroso C; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Rodríguez Sánchez Á; Medical Oncology Department, Hospital Universitario de León, León, Spain., Durán G; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., De Las Peñas R; Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain., Muñoz-Langa J; Medical Oncology Department, Hospital Universitario y Policlínico La Fe, Valencia, Spain., Velasco G; Chemical Sciences Faculty, Universidad Complutense de Madrid, Madrid, Spain., Hernández-Laín A; Department of Pathology (Neuropathology), Instituto de Investigaciones Biomédicas I+12, Hospital Universitario, 12 de Octubre, Madrid, Spain., Hilario A; Radiology Department, Universitary Hospital, 12 de Octubre, Madrid, Spain., Navarro Martín M; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain., Benavides M; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain., Oleaga L; Radiology Department, Hospital Clínic Barcelona, Barcelona, Spain., Cantero Montenegro D; Neurooncology (Molecular Biology) Department, Hospital Universitario, 12 de Octubre, Madrid, Spain., Ruano Y; Molecular Pathology Unit, Hospital Universitario 12 de Octubre Research Institute, Madrid, Spain., Sánchez-Gómez P; Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain., Martín-Soberón MC; Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain., Morales-Llombart R; MFAR Clinical Research, Barcelona, Spain., Pachón V; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pineda E; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medical Oncology Department, Hospital Clínic, Barcelona, Spain.

Publikováno v: Targeted oncology [Target Oncol] 2020 Oct; Vol. 15 (5), pp. 613-622.